| 4.865 0.075 (1.57%) | 04-24 11:33 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.88  |
1-year : | 9.51 |
| Resists | First : | 6.75 |
Second : | 8.14 |
| Pivot price | 5.23 |
|||
| Supports | First : | 4.48 | Second : | 3.73 |
| MAs | MA(5) : | 4.97 |
MA(20) : | 5.59 |
| MA(100) : | 8.35 |
MA(250) : | 7.77 |
|
| MACD | MACD : | -0.8  |
Signal : | -0.9 |
| %K %D | K(14,3) : | 17.1 |
D(3) : | 19.4 |
| RSI | RSI(14): 28.5 |
|||
| 52-week | High : | 12.98 | Low : | 3.2 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NTHI ] has closed above bottom band by 14.3%. Bollinger Bands are 60.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.95 - 4.98 | 4.98 - 5.01 |
| Low: | 4.43 - 4.47 | 4.47 - 4.5 |
| Close: | 4.73 - 4.79 | 4.79 - 4.84 |
Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.
Thu, 23 Apr 2026
Neonc Technologies Holdings president Amir Heshmatpour acquires $49,000 - Investing.com
Thu, 23 Apr 2026
Neonc Technologies (NTHI) president buys 10,000 shares in open-market trade - Stock Titan
Fri, 17 Apr 2026
[EFFECT] NEONC TECHNOLOGIES HOLDINGS, INC. SEC Filing - Stock Titan
Thu, 16 Apr 2026
CEO’s $300K NTHI buy and 2025 loss breakdown at NeOnc (NTHI) - Stock Titan
Tue, 14 Apr 2026
NeOnc chief buys $300K in shares as FDA meeting nears in 4 weeks - Stock Titan
Tue, 14 Apr 2026
NeOnc Technologies Holdings, Inc. Announces ~ $300,000 in - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 6 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 2.461e+007 (%) |
| Held by Institutions | 8.15e+006 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 39990 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -3.21 |
| Profit Margin | 0 % |
| Operating Margin | -145 % |
| Return on Assets (ttm) | 637.5 % |
| Return on Equity (ttm) | -1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.01 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | -1.51 |
| Price to Sales | 165631 |
| Price to Cash Flow | 0 |
| Dividend | 289780 |
| Forward Dividend | 214970 |
| Dividend Yield | 5999590% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|